EUVIMEDEUVIMED entdecken
Open Access

Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease

Taihua Yang iD, Jiahao Ge iD, Lei Huang iD, Xinye Zhu iD, Dexin Zhang iD, Siyuan Tang, Jie Zhao, Yinhe Ma, Mei Long, Xiaochen Bo, Jie Li, Yiqing Zhang und 11 weitere

Science Advances · 2025

DOI: 10.1126/sciadv.adt9694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Taihua Yang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. Hauptthemen laut MEDLINE: Hyperoxaluria, Primary, Transaminases, RNA, Messenger. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary hyperoxaluria type 1 (PH1) is a rare inherited liver disorder caused by alanine glyoxylate aminotransferase (AGT) dysfunction, leading to accumulation of glyoxylate which is then converted into oxalate. Excessive oxalate results in kidney damage due to deposition of oxalate crystals. We have developed an mRNA-based protein replacement therapy for PH1 to restore normal glyoxylate to glycine metabolism. Sequence optimized human AGT mRNA ( hAGT mRNA) was encapsulated in lipopolyplex (LPP) and produced functional AGT enzyme in peroxisomes. Pharmacokinetics and pharmacodynamics (PK/PD) were evaluated in vitro and in vivo. PK demonstrated that AGT mRNA and AGT protein maintained high expression levels for up to 48 hours. A single 2 mg/kg dose in Agxt Q84 −/− rats achieved a 70% reduction in urinary oxalate. Toxicological assessment identified the highest nonserious toxic dose (HNSTD) as 2 mg/kg. These findings affirm the efficacy and safety of hAGT mRNA/LPP and support its clinical application in PH1 treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperoxaluria, PrimaryTransaminasesRNA, MessengerAnimalsHumansRatsMaleOxalatesDisease Models, Animal

Substanzen

TransaminasesAlanine-glyoxylate transaminaseRNA, MessengerOxalates

Autor:innen und Institutionen

  • Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
  • Stemirna Therapeutics, Shanghai 201203, China.
  • Department of Material Science, Fudan University, Shanghai 200433, China.
  • Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
  • Department of Clinical research unit, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
  • Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany.

ORCID-Profile: Taihua Yang, Jiahao Ge, Lei Huang, Xinye Zhu, Dexin Zhang, Qinggong Yuan, Michael Ott, Hongquan Geng, Yicheng Zhao, Liang Zhang, Haifa Shen, Hangwen Li, Dali Li, Ping Wan, Qiang Xia

Zitieren

APA

Yang, T., Ge, J., Huang, L., Zhu, X., Zhang, D., Tang, S., Zhao, J., Ma, Y., Long, M., Bo, X., Li, J., Zhang, Y., Yuan, Q., Sharma, A. D., Ott, M., Geng, H., Zhao, Y., Zhang, L., Shen, H., …, & Xia, Q. (2025). Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease. Science Advances. https://doi.org/10.1126/sciadv.adt9694

Vancouver

Yang T, Ge J, Huang L, Zhu X, Zhang D, Tang S, et al. Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease. Science Advances. 2025. doi:10.1126/sciadv.adt9694

BibTeX
@article{Yang2025,
  author = {Yang, Taihua and Ge, Jiahao and Huang, Lei and Zhu, Xinye and Zhang, Dexin and Tang, Siyuan and Zhao, Jie and Ma, Yinhe and Long, Mei and Bo, Xiaochen and Li, Jie and Zhang, Yiqing and Yuan, Qinggong and Sharma, Amar Deep and Ott, Michael and Geng, Hongquan and Zhao, Yicheng and Zhang, Liang and Shen, Haifa and Li, Hangwen and Li, Dali and Wan, Ping and Xia, Qiang},
  title = {Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adt9694}
}
Kostenlos starten →